Get started
Author

Ioana Kloos

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
2017 · A. Younes, P. Hilden, et al. · Annals of Oncology · 370
PDF
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study
2022 · Michael Wang, Javier Munoz, et al. · Journal of Clinical Oncology · 331
Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study
2009 · Karine Briot, Michèle Tubiana-Hulin, et al. · Breast Cancer Research and Treatment · 115
Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study
2017 · Vincent Ribrag, Won Seog Kim, et al. · Haematologica · 97
PDF
Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: Report of five cases and review of the literature
2002 · I. Kloos, S. Delaloge, et al. · International Journal of Gynecological Cancer · 73
Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma
2019 · Esperanza M Algarín, Andrea Díaz-Tejedor, et al. · Haematologica · 60
PDF
Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia
2015 · Franck Morschhauser, Louis Terriou, et al. · Investigational New Drugs · 39
Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I
2013 · Sylvain Fouliard, Renata Robert, et al. · European Journal of Cancer · 33
Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study
2025 · Julio C. Chavez, Michael Dickinson, et al. · Blood · 24
Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat
2017 · Sofia Rivera, Céline Leteur, et al. · Oncotarget · 22
PDF
Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia
2016 · Norbert Vey, Thomas Prebet, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 22
PDF
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis
2025 · Nausheen Ahmed, Swetha Kambhampati Thiruvengadam, et al. · Blood Advances · 20
PDF
3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)
2023 · Julio C. Chavez, Michael Dickinson, et al. · Blood · 15
Outcomes of Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 and ZUMA-18, an Expanded Access Study
2023 · Andre Goy, Caron A. Jacobson, et al. · Blood · 15
One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma
2020 · Michael Wang, Javier Munoz, et al. · Blood · 14
Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients
2014 · Quentin Chalret du Rieu, Sylvain Fouliard, et al. · Investigational New Drugs · 14
A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors
2016 · Eric Deutsch, Elizabeth Cohen-Jonathan Moyal, et al. · Oncotarget · 13
PDF
Real-World Outcomes of Brexucabtagene Autoleucel (brexu-cel) for Relapsed or Refractory (R/R) Adult B-Cell Acute Lymphoblastic Leukemia (B-cell ALL): Evidence from the CIBMTR Registry
2023 · Evandro Bezerra, Taha Itani, et al. · Blood · 12
Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2
2024 · Michael Wang, Andre Goy, et al. · Blood · 11
Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England
2022 · Svenja Petersohn, Gilles Salles, et al. · Journal of Medical Economics · 11
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3
2025 · Tom van Meerten, Marie José Kersten, et al. · Blood · 10
Outcomes with KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24).
2021 · Michael Wang, Javier Munoz, et al. · Journal of Clinical Oncology · 10
A New Bcl‐2 Inhibitor (s55746/bcl201) as Monotherapy in Patients With Relapsed or Refractory Non‐hodgkin Lymphoma: Preliminary Results of the First‐in‐human Study
2017 · S. Le Gouill, M. Wermke, et al. · Hematological Oncology · 10
PDF
Application of Hematological Toxicity Modeling in Clinical Development of Abexinostat (S-78454, PCI-24781), A New Histone Deacetylase Inhibitor
2013 · Quentin Chalret du Rieu, Sylvain Fouliard, et al. · Pharmaceutical Research · 10
Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
2025 · Nora Liebers, Ariane Boumendil, et al. · Blood Cancer Discovery · 9
Works count: 90
Citation count: 1,441
H-index: 14
I10-index: 24
Year
Topic
Type